GLP-1 & Incretin Science

Why Orthopaedic Surgeons Started Paying Attention

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Gatto and colleagues reviewed the effects of GLP-1 agonists on musculoskeletal health and orthopaedic care in Current Reviews in Musculoskeletal Medicine in 2025. This is a specialty that encounters these compounds through joint disease, surgical planning and perioperative management rather than through metabolic care.

Key facts

Review
Gatto 2025 (PMID 40372699)
Journal
Curr Rev Musculoskelet Med, October 2025
Scope
Musculoskeletal health and orthopaedic care
Relevance
Joint load, bone, muscle, perioperative
Perioperative issue
Delayed gastric emptying and anaesthesia
Weight-bearing joints
Load reduction is mechanical

Why a musculoskeletal specialty has its own view

Orthopaedics encounters obesity constantly: as a driver of joint degeneration, as a factor in surgical risk, and as a determinant of implant outcomes. A drug class producing 15 to 25% weight reduction changes all three at once, which makes it a specialty concern independent of anything metabolic.

Why weight matters mechanically at the knee

The knee experiences forces several times body weight during ordinary walking, because muscle contraction across the joint adds to the load gravity imposes. Reducing body mass therefore reduces joint force by a multiple of the mass lost. That is a mechanical argument, and it does not depend on any effect of the drug beyond the weight change.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The perioperative question

Delayed gastric emptying means stomach contents may remain longer than fasting guidance assumes, which matters for anaesthesia because it affects aspiration risk. That is a scheduling and assessment problem for surgical teams rather than a pharmacological one, and it arises for any procedure requiring sedation.

The competing considerations for surgery

Weight reduction before joint replacement may improve outcomes and reduce complications. Against that sit the bone and lean mass changes accompanying rapid weight loss, and the perioperative gastric emptying issue. A specialty review is where those are weighed together rather than considered one at a time.

Why this is a different question from the metabolic one

Metabolic medicine asks whether the drug improves glycaemia, cardiovascular risk or organ outcomes. Orthopaedics asks whether a patient is a better surgical candidate afterwards, and whether the tissue being operated on has changed. Those are separate questions and neither literature answers the other's.

What this does not concern

Research material. These are licensed medicines encountered in clinical practice. Nothing supplied on this site is a GLP-1 receptor agonist, is relevant to surgical planning, or has any bearing on the care of any person.

Frequently asked questions

Why do orthopaedic specialists care about GLP-1 drugs?

Obesity drives joint degeneration, surgical risk and implant outcomes. A drug producing 15-25% weight reduction changes all three.

How much does weight loss reduce knee load?

By a multiple of the mass lost, because the knee experiences forces several times body weight during walking as muscle contraction adds to gravitational load.

What is the perioperative concern?

Delayed gastric emptying means stomach contents may persist beyond what fasting guidance assumes, which affects aspiration risk under anaesthesia.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.